Table.
Time to Reporting of Normal Functioning (Hours)
| N | Time to First Report of Normal Functioning* Median (95% CI) | P Value† vs Sumatriptan/Naproxen Sodium | Time to Sustained Report of Normal Functioning* Median (95% CI) | P Value† vs Sumatriptan/Naproxen Sodium | ||
|---|---|---|---|---|---|---|
| Study 1 | ||||||
| Sumatriptan/naproxen sodium | 342 | 4 (3-5) | 5 (4-7) | |||
| Sumatriptan | 338 | 4 (4-5) | ns | 7 (6-9) | ns | |
| Naproxen | 345 | 7 (6-8) | < .001 | 11 (8-13) | .005 | |
| Placebo | 355 | 11 (9-13) | < .001 | 16 (14-18) | < .001 | |
| Study 2 | ||||||
| Sumatriptan/naproxen sodium | 341 | 3 (3-4) | 4 (3-4) | |||
| Sumatriptan | 333 | 5 (4-6) | .002 | 8 (7-12) | .001 | |
| Naproxen | 331 | 5 (5-7) | < .001 | 9 (7-11) | < .001 | |
| Placebo | 328 | 11 (9-13) | < .001 | 14 (12-16) | < .001 | |
*
Normal functioning = not impaired response on ability to function measure
†
Log-rank test controlling for censoring at 24 hours; subjects reporting normal functioning (not impaired) at dosing (time = 0) were excluded.
CI = confidence interval; ns = not statistically significant